UA102849C2 - Способ продолжительного лечения эндометриоза и фибромы матки - Google Patents

Способ продолжительного лечения эндометриоза и фибромы матки

Info

Publication number
UA102849C2
UA102849C2 UAA201014039A UAA201014039A UA102849C2 UA 102849 C2 UA102849 C2 UA 102849C2 UA A201014039 A UAA201014039 A UA A201014039A UA A201014039 A UAA201014039 A UA A201014039A UA 102849 C2 UA102849 C2 UA 102849C2
Authority
UA
Ukraine
Prior art keywords
endometriosis
treatment
estrogen
uterine fibroids
methods
Prior art date
Application number
UAA201014039A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Джозеф С. Подольски
Original Assignee
Репрос Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Репрос Терапьютикс Инк. filed Critical Репрос Терапьютикс Инк.
Publication of UA102849C2 publication Critical patent/UA102849C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
UAA201014039A 2008-04-28 2009-04-27 Способ продолжительного лечения эндометриоза и фибромы матки UA102849C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28
PCT/US2009/041826 WO2009134718A1 (en) 2008-04-28 2009-04-27 Pregesteron antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc

Publications (1)

Publication Number Publication Date
UA102849C2 true UA102849C2 (ru) 2013-08-27

Family

ID=40751037

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201014039A UA102849C2 (ru) 2008-04-28 2009-04-27 Способ продолжительного лечения эндометриоза и фибромы матки

Country Status (24)

Country Link
US (2) US8426394B2 (cg-RX-API-DMAC10.html)
EP (1) EP2293797B1 (cg-RX-API-DMAC10.html)
JP (1) JP5791499B2 (cg-RX-API-DMAC10.html)
KR (2) KR20130059442A (cg-RX-API-DMAC10.html)
CN (2) CN102014923A (cg-RX-API-DMAC10.html)
AR (1) AR071516A1 (cg-RX-API-DMAC10.html)
AU (1) AU2009241355B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0911563A2 (cg-RX-API-DMAC10.html)
CA (1) CA2722753C (cg-RX-API-DMAC10.html)
CL (1) CL2009001010A1 (cg-RX-API-DMAC10.html)
DK (1) DK2293797T3 (cg-RX-API-DMAC10.html)
EA (3) EA201990835A3 (cg-RX-API-DMAC10.html)
ES (1) ES2561810T3 (cg-RX-API-DMAC10.html)
IL (1) IL208844A0 (cg-RX-API-DMAC10.html)
ME (1) ME01123B (cg-RX-API-DMAC10.html)
MX (1) MX2010011272A (cg-RX-API-DMAC10.html)
MY (1) MY161059A (cg-RX-API-DMAC10.html)
NI (1) NI201000183A (cg-RX-API-DMAC10.html)
NZ (1) NZ589533A (cg-RX-API-DMAC10.html)
SG (1) SG10201408483QA (cg-RX-API-DMAC10.html)
TW (1) TWI477276B (cg-RX-API-DMAC10.html)
UA (1) UA102849C2 (cg-RX-API-DMAC10.html)
WO (1) WO2009134718A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201007529B (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2872644A1 (en) * 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko) 2014-07-29 2017-04-12 쎄러퓨틱스엠디, 인코퍼레이티드 경피 크림
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
KR100358319B1 (ko) * 1993-11-16 2002-10-25 쉐링 악티엔게젤샤프트 산화질소 합성효소 기질, 산화질소 공여체, 또는 산화질소저해제를 포함하는 자궁 수축성 질환의 치료용 약물
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
ATE235907T1 (de) * 1995-02-02 2003-04-15 Schering Ag Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
ES2152671T3 (es) * 1996-05-01 2001-02-01 Us Gov Health & Human Serv Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
AU2805397A (en) 1996-08-30 1998-03-19 Population Council, Center For Biomedical Research, The Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
ATE396197T1 (de) * 2000-03-17 2008-06-15 Us Gov Health & Human Serv 17-alpha-substituierte-11-beta-substituierte-4- aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität
IN191020B (cg-RX-API-DMAC10.html) * 2000-03-28 2003-09-13 Dabur Res Foundation
AU5299401A (en) 2000-04-03 2001-10-15 Astenjohnson Inc Pre-crimped tie components
CA2423017C (en) * 2000-10-18 2009-01-06 Bayer Schering Pharma Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
CN1289075C (zh) 2001-07-09 2006-12-13 佐纳根有限公司 富含反式克罗米酚的克罗米酚组合物的用途
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
JP5017109B2 (ja) * 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド プロゲステロン受容体モジュレーターを含有する徐放性組成物
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
MY150763A (en) * 2006-10-24 2014-02-28 Repros Therapeutics Inc Compositions and methods for suppressing endometrial proliferation
AU2008206599A1 (en) * 2007-01-17 2008-07-24 Repros Therapeutics Inc. Pharmaceutically acceptable salts of 11- (4-aminophenyl) -19-n0rpregna-4,9 (10) -diene-3, 20-dione derivatives
EP2144601A4 (en) 2007-04-05 2012-10-10 Univ Kansas RAPID DISSOLVING PHARMACEUTICAL COMPOSITIONS COMPRISING PULLULANE
SI2148681T1 (sl) * 2007-04-20 2016-07-29 Preglem S.A. Selektivni modulatorji progesterona v zdravljenju maternične krvavitve
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
US20130066302A1 (en) 2009-09-29 2013-03-14 MEDIMETRICS Personalized Drug Delivery B.V. Intrauterine electronic capsule for administering a substance

Also Published As

Publication number Publication date
ES2561810T3 (es) 2016-03-01
ZA201007529B (en) 2011-07-27
TW200950786A (en) 2009-12-16
US8735381B2 (en) 2014-05-27
US20130289008A1 (en) 2013-10-31
IL208844A0 (en) 2011-01-31
CN102014923A (zh) 2011-04-13
WO2009134718A8 (en) 2010-09-23
CA2722753C (en) 2018-07-03
AR071516A1 (es) 2010-06-23
JP5791499B2 (ja) 2015-10-07
EP2293797A1 (en) 2011-03-16
KR20130059442A (ko) 2013-06-05
EA032646B1 (ru) 2019-06-28
EA201071249A1 (ru) 2011-08-30
TWI477276B (zh) 2015-03-21
NI201000183A (es) 2012-06-06
MX2010011272A (es) 2010-12-21
MY161059A (en) 2017-04-14
SG10201408483QA (en) 2015-02-27
US20110046098A1 (en) 2011-02-24
DK2293797T3 (en) 2016-01-11
EA201990835A2 (ru) 2019-08-30
CL2009001010A1 (es) 2009-06-19
CN105616427A (zh) 2016-06-01
CA2722753A1 (en) 2009-11-05
ME01123B (me) 2013-03-20
JP2011518845A (ja) 2011-06-30
NZ589533A (en) 2012-06-29
BRPI0911563A2 (pt) 2016-07-12
EP2293797B1 (en) 2015-11-11
EA201990835A3 (ru) 2019-12-30
EA201401347A1 (ru) 2015-07-30
KR20110014162A (ko) 2011-02-10
AU2009241355A1 (en) 2009-11-05
US8426394B2 (en) 2013-04-23
WO2009134718A1 (en) 2009-11-05
AU2009241355B2 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
MY161059A (en) Progesterone antagonists such as cdb-4214 in the treatment of embodimetriosis, uterine fibroids, dysmenorrhea, breast cancer etc
MY150763A (en) Compositions and methods for suppressing endometrial proliferation
MY161549A (en) Progesterone antagonists such as cdb-4124 in the treatment of breast cancer
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
MX2014004202A (es) Uso post-agudo y profiláctico de progesterona para mejores resultados asociados con concusión.
MX2009009581A (es) Indazoles usados para tratar trastornos mediados por el receptor de estrogenos beta.
GB201104241D0 (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
WO2007133816A3 (en) Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
WO2011031524A3 (en) Methods and compositions for delivering interleukin-1 receptor antagonist
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2012006320A (es) Composiciones de amantadina y metodos para su uso.
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
EA201171215A1 (ru) Стоматологическое анестезирующее средство для интраназального введения, содержащее тетракаин и вазоконстриктор
EP2582371A4 (en) METHOD FOR TREATING OR PREVENTING ESTROGEN-MEDIATED DISEASES
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
EA201590522A1 (ru) Способы введения рифаксимина для снижения веса и лечения ожирения
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2009134725A3 (en) Monomethylamine progesteron antagonists such as cdb-4453 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
MX2009009332A (es) Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis.
PT2435443E (pt) Inibidores à base de aminopirazole triazolotiadiazole da proteína quinase c met
MX367580B (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento del cáncer.
TN2017000482A1 (en) Selective progesterone receptor modulator (sprm) regimen.
UA98124C2 (ru) Применение антагониста прогестерона для лечения эндометриоза
TN2015000454A1 (en) Progesterone receptor antagonist dosage form
UA90568U (uk) Спосіб комплексної терапії овець та кіз з гіполютеолізом